Crescent Biopharma Inc. (CBIO) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Crescent Biopharma Inc.

    NASDAQ: CBIO · Real-Time Price · USD
    14.24
    0.55 (4.02%)
    At close: Sep 05, 2025, 3:59 PM
    14.24
    0.00%
    After-hours: Sep 05, 2025, 04:10 PM EDT

    Crescent Biopharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 105.76M 794K 7.34M
    Cost of Revenue
    		 3.88M 798K 7.38M
    Gross Profit
    		 101.87M -4K -42K
    Operating Income
    		 16.16M -8.61M -87.89M
    Interest Income
    		 n/a 537K 39K
    Pretax Income
    		 23.22M -7.89M -87.93M
    Net Income
    		 28.54M -8.24M -87.89M
    Selling & General & Admin
    		 73.62M 17.37M 18.96M
    Research & Development
    		 12.02M 13.04M 68.89M
    Other Expenses
    		 66K n/a -78K
    Operating Expenses
    		 85.71M 30.4M 87.85M
    Interest Expense
    		 n/a 717K n/a
    Selling & Marketing Expenses
    		 57.51M n/a n/a
    Cost & Expenses
    		 89.59M 31.2M 95.23M
    Income Tax Expense
    		 -5.32M 348K -39K
    Shares Outstanding (Basic)
    		 850.95K 315.46K 306.41K
    Shares Outstanding (Diluted)
    		 1.02M 315.46K 306.41K
    EPS (Basic)
    		 34.00 -26 -287
    EPS (Diluted)
    		 28.00 -26 -287
    EBITDA
    		 16.16M -52.15M -87.6M
    EBIT
    		 n/a -7.18M -87.97M
    Depreciation & Amortization
    		 n/a -43.54M 290K

    Add to Watchlist